Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis

Inclusion criteria

• in Phase 1: Attack Treatment (open)

• over the age of eighteen patient,
• Seborrheic dermatitis Severe,
• participation with an informed consent,
• Women of childbearing age in effective contraception for the duration of the study or postmenopausal women.
• in Phase 2: Phase 2: "Randomization" (blind)

• Patient achieved a complete or almost complete clinical remission after the initial treatment,
• known immunodeficiency (HIV patient receiving chemotherapy) or immunosuppressive therapy or biotherapy,
• patient taking regular systemic corticosteroids at a dose> 20 mg / day
• erythematous lesions with topography other than the face and evocative scalp psoriasis (elbows, knees ...), by referring to the possibility that the facial lesions correspond to lesions sebopsoriasis,
• woman pregnant, nursing or in childbearing potential without effective contraception,
• man wishing to have a child during the study period,
• Ultra Violet (UV) phototherapy or usual realization of UV sessions aesthetic purposes,
• Seborrheic dermatitis symptomatic of an underlying disease known or revealing
• history of cancer or lymphoma,
• progressive cancer or lymphoma,
• Seborrheic dermatitis exclusively affecting the scalp,
• known allergy to one-component products study ,
• malnourished patient or sick history of chronic pancreatitis by a suspect to deficiency dermatitis,
• participation in a clinical trial on the Seborrheic dermatitis in the previous 90 days,
• patient with lesions considered potentially malignant or pre-cancerous,
• patient with abnormal skin barrier.

Exclusion criteria

• in Phase 1: Attack Treatment (open)

• Patient had already been treated with Protopic ® for Seborrheic Dermatitis,
• Phase 2: "Randomization" (blind) 1) Patient with no complete or almost complete clinical remission after the initial treatment,